IN10028 / InxMed - LARVOL DELTA

FAK Inhibitor in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=75 | Not yet recruiting | Sponsor: InxMed (Shanghai) Co., Ltd.

Monotherapy • New P1 trial • Oncology • Solid Tumor

IN10028, a next-generation FAK inhibitor discovered for the treatment of solid tumors (AACR 2026) - "Compared to IN10018, a first-generation FAK inhibitor, IN10028 shows superior cancer cell cytotoxicity. Through experiments conducted in animal models, IN10028 was evaluated in both monotherapy and combination therapy settings, consistently outperforming multiple first-generation FAK inhibitors in terms of tumor growth inhibition. Additionally, pharmacokinetic and toxicity studies necessary for Investigational New Drug (IND) filing have been completed, with the IND application anticipated in December 2025."

Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor